secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001619856-23-000084
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou announces positive long-term follow-up for CB-010 in ANTLER Phase 1
---------------------------------------------------------------------------

- Positive long-term follow-up results from dose escalation of ANTLER Phase 1 for CB-010 in relapsed/refractory B-NHL.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy; study remains ongoing.
- Detailed clinical data summary filed as Exhibit 99.1; specific results not provided in the filing excerpt.
- Announcement made on July 13, 2023; no financial or regulatory guidance changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000084/0001619856-23-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000084/crbu-20230713.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer